Cyxone’s focus is to bring T20K to clinical trials in multiple sclerosis
Cyxone AB is a Swedish company founded in 2015 to develop cyclotide drugs for autoimmune and other diseases. The company operates through an international network of experts in research and development including the scientific founders in Austria and in Germany. The company is based on a solid research platform with a class of biological molecules that have been shown to be practically useful as drugs in man.
Cyxone will focus on bringing T20K through preclinical studies required to start clinical trials in MS patients. In addition, Cyxone will also use its cyclotide technology to find new structures that can benefit patients with other major diseases.